Mapping from the health assessment questionnaire to the eq-5d: The impact of different algorithms on cost-effectiveness results

Value in Health

Volumn 17, Issue 8, 2014, Pages 762-771

  Pennington, Becky ^a   Davis, Sarah ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

cost effectiveness; EQ 5D; rheumatoid arthritis; simulation utility

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD; LEFLUNOMIDE; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ALGORITHM; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG TREATMENT FAILURE; ECONOMIC EVALUATION; ECONOMIC MODEL; EQ 5D; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HEALTH STATUS; HUMAN; MODEL; PAIN; QUALITY ADJUSTED LIFE YEAR; QUESTIONNAIRE; REIMBURSEMENT; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; VISUAL ANALOG SCALE; AGE; ARTHRITIS, RHEUMATOID; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH STATUS INDICATOR; PAIN MEASUREMENT; QUALITY OF LIFE; SEX DIFFERENCE; STATISTICAL MODEL;

AGE FACTORS; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; HEALTH STATUS INDICATORS; HUMANS; MODELS, ECONOMIC; PAIN MEASUREMENT; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; SEX FACTORS;

EID: 84915792962     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2014.11.002     Document Type: Article

References (51)

1. Stanford University School of Medicine Division of Immunology & Rheumatology. The Health Assessment Questionnaire. Available from: http://www.chcr.brown.edu/pcoc/ehaqdescrscoringhaq372.pdf. [Accessed November 16, 2012]
2. The National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Available from: http://publications.nice.org.uk/guide-to-the-methods-of-technology-appraisal-2013-pmg9/introduction. [Accessed March 31, 2014].
3. J.E. Brazier, Y. Yang, and A. Tsuchiya A review of studies mapping (or cross walking) non-preferences based measures of health to generic preference-based measures Eur J Health Econ 11 2010 215 225
4. L. Longworth, and D. Rowen Mapping to obtain EQ-5D utility values for use in NICE health technology assessments Value Health 16 2013 202 210
5. Stevenson MD, Archer R, Tosh J. et al. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying anti-rheumatic drugs and after the failure of conventional disease-modifying anti-rheumatic drugs only: systematic review and economic evaluation. Sheffield, UK: University of Sheffield, 2013.
6. Scottish Medicines Consortium. Guidance to manufacturers. Available from: http://www.scottishmedicines.org.uk/Submission-Process/Submission-Guidance-and-Templates-for-Industry/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission. [Accessed March 31, 2014].
7. Australian Government Department of Health. PBAC guidelines appendix 7. Available from: http://www.pbac.pbs.gov.au/appendixes/appendix-7.html. [Accessed March 31, 2014].
8. Canadian Agency for Drugs and Technologies in Health. Common drug review submission guidelines for manufacturers. Available from: http://www.cadth.ca/media/cdr/process/CDR-Submission-Guidelines-e.pdf. [Accessed March 31, 2014].
9. National Institute for Health and Care Excellence. Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a TNF Inhibitor. London, UK: National Institute of Health and Care Excellence, 2010.
10. K. Malottki, P. Barton, and A. Tsourapas Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Health Technol Assess 15 2011 1 278
11. M. Hernández Alava, A.J. Wailoo, and R. Ara Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values Value Health 15 2012 550 561
12. Ducornau P., Kielhorn A., Wintfeld N. Comparison of linear and non-linear utility mapping between HAQ and EQ-5D using pooled data from the tolicizumab trials OPTION and LITHE. In: Annual Meeting of the British Society of Rheumatology (BSR), Glasgow, April 28-May 1, 2009.
13. A. Brennan, N. Bansback, A. Reynolds, and P. Conway Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology 43 2004 62 72
14. N. Bansback, C. Marra, and A. Tsuchiya Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis Arthritis Rheum 57 2007 963 971
15. N.P. Hurst, P. Kind, and D. Ruta Measuring health related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol Br J Rheumatol 36 1997 551 559
16. G. Hawthorne, R. Buchbinder, and J. Defina Functional Status and Health-related Quality of Life Assessment in Patients with Rheumatoid Arthritis (Working Paper 116) Monash University Centre for Health Program Evaluation, 2000
17. P. Lindgren, P. Geborek, and G. Kobelt Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden Int J Technol Assess 25 2009 181 189
18. C.A. Marra, S.A. Marion, and D.P. Guh Not all "quality-adjusted life years" are equal J Clin Epidemiol 60 2007 616 624
19. A.J. Wailoo, N. Bansback, and A. Brennan Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis Arthritis Rheumatol 58 2008 939 946
20. A. Carreño, I. Fernández, and X. Badia Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain Value Health 14 2011 192 200
21. L. Standfield, S. Norris, and C. Harvey Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: a cross-sectional, multicentre study Clin Ther 32 2010 1329 1342
22. M. Tanno, I. Nakamura, and K. Ito Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis Mod Rheumatol 16 2006 77 84
23. R. Adams, C. Walsh, and D. Veale Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis Pharmacoeconomics 28 2010 477 487
24. M.F. Drummond, M. Barbieri, and J.B. Wong Analytic choices in economic models of treatments for rheumatoid arthritis: what makes a difference? Med Decis Making 25 2005 520 533
25. A. Konnopka, K. Conrad, C. Baerwalk, and H.-H. Koenig Cost effectiveness of the determination of antibodies against cyclic citrullinated peptide in the early diagnosis of rheumatoid arthritis Ann Rheum Dis 67 2008 1399 1405
26. G. Kobelt, P. Lindgren, and Y. Lindroth Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis Rheumatology 44 2005 1169 1175
27. G. Kobelt, P. Lindgren, A. Singh, and L. Klareskog Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial Ann Rheum Dis 64 2005 1174 1179
28. G. Kobelt, L. Joensson, and P. Lindgren Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis Arthritis Rheum 46 2002 2310 2319
29. M. Vera-Llonch, E. Massarotti, and F. Wolfe Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate Rheumatol 47 2008 535 541
30. W. Clark, P. Jobanputra, P. Barton, and A. Burls The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis Health Technol Assess 8 2004 iii-iv, ix-x, 1-105
31. Liverpool Reviews and Implementation Group on behalf of The National Institute for Health and Care Excellence. Abatacept for the Treatment of Rheumatoid Arthritis: ERG Report. Liverpool, UK: Liverpool Reviews and Implementation Group, 2007.
32. Y.-F. Chen, P. Jobanputra, and P. Barton A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness Health Technol Assess 10 2006 iii-iv, xi-xiii, 1-229
33. Methods for obtaining health state values: generic preference-based measures of health and the alternatives J. Brazier, J. Ratcliffe, J.A. Salomon, and A. Tsuchiya Measuring and Valuing Health Benefits for Economic Evaluation 2007 Oxford University Press New York
34. M. Hernández Alava, A. Wailoo, and F. Wolfe The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis Rheumatology 52 2013 944 950
35. J. Tosh, J. Brazier, and P. Evans A review of generic preference-based measures of health-related quality of life in visual disorders Value Health 15 2012 118 127
36. S. Davis, and A. Wailoo A review of the psychometric performance of EQ-5D in people with urinary incontinence Health Qual Life Outcomes 11 2013 20
37. S. Bombardieri, A.A. Ruiz, and P. Fardellone Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNFantagonist therapy in clinical practice Rheumatol 46 2007 1191 1199
38. B. Haraoui, E.C. Keystone, and J.C. Thorne Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept J Rheumatol 31 2004 2356 2359
39. C.O. Bingham III, A. Ince, and B. Haraoui Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study Curr Med Res Opin 25 2009 1131 1142
40. E. Keystone, G.R. Burmester, and R. Furie Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy Arthritis Care Res (Hoboken) 59 2008 785 793
41. E. Keystone, P. Emery, and C.G. Peterfy Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies Ann Rheum Dis 68 2009 216 221
42. S.B. Cohen, P. Emery, and M.W. Greenwald Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2006 2793 2806
43. A.L. Hassett, T. Li, and S. Buyske The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study Curr Med Res Opin 24 2008 1443 1453
44. P. Emery Abatacept has beneficial effects in rheumatoid arthritis patients with an inadequate response to anti-TNFalpha therapy Clin Exp Rheumatol 23 2005 767 768
45. R. Westhovens, J.C. Cole, and T. Li Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial Rheumatology 45 2006 1238 1246
46. M.C. Genovese, J.-C. Becker, and M. Schiff Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 2005 1114 1123
47. Bristol-Myers Squibb. A phase III, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BMS-188667 in subjects with active rheumatoid arthritis on background DMARDS who have failed anti-TNF therapy. Clinical Study Report IM01029 2004. Available from: http://ctr.bms.com/pdf//IM101029LT.pdf. [Accessed October 1, 2009].
48. M.C. Genovese, J.-C. Becker, and M. Schiff Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 353 2005 2311
49. A. Brennan, J. Madan, and N. Bansback Modelling the Cost-Effectiveness of Sequential Use of TNF-Alpha Inhibitors in the Management of Rheumatoid Arthritis: An Update HEDS Discussion Paper Series 6/12. 2006
50. P. Barton, P. Jobanputra, and J. Wilson The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis Health Technol Assess 8 2004 iii, 1-91
51. R. Ariza-Ariza, F. Navarro-Sarabia, and B. Hernandez-Cruz Dose escalation of the anti-TNF- agents in patients with rheumatoid arthritis: a systematic review Rheumatol 46 2007 529 532